Open AccessThe Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma
Author(s) -
Elin Edda Sigurdardottir,
Ingemar Turesson,
Sigrún H. Lund,
Ebba K. Lindqvist,
Sham Mailankody,
Neha Korde,
Magnus Björkholm,
Ola Landgren,
Sigurður Y. Kristinsson
Publication year - 2015
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2015.23
Subject(s) - medicine , monoclonal gammopathy of undetermined significance , multiple myeloma , hazard ratio , proportional hazards model , comorbidity , population , oncology , monoclonal , monoclonal antibody , immunology , confidence interval , antibody , environmental health
Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom